| Product Information | |
|---|---|
| Composition | Nebivolol Hydrochloride & Hydrochlorothiazide Tablets | 
| Dosage Form | Tablet | 
| Packing Size | 10 x 10 | 
| Packing | Blister | 
NEVOVIV H-5/12.5 is a combination antihypertensive medication containing Nebivolol Hydrochloride 5 mg and Hydrochlorothiazide 12.5 mg. This formulation is designed to provide comprehensive blood pressure management, effectively reducing hypertension and lowering the risk of heart attack, stroke, and kidney complications.
Nebivolol Hydrochloride is a beta-1 selective blocker that reduces heart rate and cardiac workload.
Hydrochlorothiazide (HCTZ) is a thiazide diuretic that promotes the excretion of excess sodium and water.
Together, they provide dual-action blood pressure control for patients requiring enhanced antihypertensive therapy.
Each tablet contains:
Nebivolol Hydrochloride 5 mg – Beta-1 selective blocker that decreases heart rate, cardiac output, and blood pressure.
Hydrochlorothiazide 12.5 mg – Thiazide diuretic that reduces fluid retention and decreases blood volume.
Tablet
Antihypertensive / Beta-Blocker + Diuretic Combination
NEVOVIV H-5/12.5 Tablets are indicated for:
Management of hypertension (high blood pressure)
Patients requiring combination therapy for optimal blood pressure control
Reduction of cardiovascular risk, including heart attack and stroke
Prevention of hypertension-related kidney complications
Nebivolol Hydrochloride selectively blocks beta-1 adrenergic receptors, reducing heart rate and cardiac output, thereby lowering blood pressure.
Hydrochlorothiazide promotes excretion of sodium and water, decreasing blood volume and vascular resistance.
The combination provides synergistic antihypertensive effects, addressing both cardiac workload and fluid retention.
Recommended Dose: As prescribed by the physician, usually once daily
Route: Oral
Duration: Long-term therapy as advised by a healthcare provider
Note: Regular monitoring of blood pressure, electrolytes, and kidney function is recommended.
Provides dual-action blood pressure control
Reduces risk of heart attack, stroke, and kidney disease
Suitable for patients uncontrolled by monotherapy
Convenient once-daily dosing enhances adherence
NEVOVIV H-5/12.5 is generally well tolerated. Possible side effects include:
Dizziness or lightheadedness
Fatigue or tiredness
Headache
Increased urination
Rarely, electrolyte imbalances or hypotension
Consult your physician if side effects persist or worsen.
Avoid use in pregnancy
Use with caution in renal or liver impairment
Inform your doctor about other medications to prevent drug interactions
Regular monitoring of blood pressure, electrolytes, and kidney function is advised
Store below 25°C, in a dry place away from sunlight. Keep out of reach of children.
Brand Name: NEVOVIV H-5/12.5
Composition: Nebivolol Hydrochloride 5 mg + Hydrochlorothiazide 12.5 mg
Dosage Form: Tablet
Therapeutic Class: Antihypertensive / Beta-Blocker + Diuretic
Manufacturer: [Insert Company Name]
Packaging: [Example: 10×10 Tablets / Strip]
Provides effective dual-action blood pressure management
Helps maintain healthy heart and kidney function
Convenient once-daily tablet
Manufactured under strict GMP-certified quality standards
NEVOVIV H-5/12.5 (Nebivolol Hydrochloride 5 mg + Hydrochlorothiazide 12.5 mg Tablets) delivers safe and effective management of hypertension. By combining a beta-blocker and diuretic, it helps control blood pressure, protect cardiovascular health, and prevent kidney complications, supporting long-term wellness.